Expand BIIB Menu
BIIB MENU

BIIB Latest Press Releases

-- March 12, 2026 --

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Avantor, Inc. (AVTR), Baxter International Inc. (BAX), Biogen Inc. (BIIB), and CarMax, Inc. (KMX) Globe Newswire 10:29 AM

-- March 11, 2026 --

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy Globe Newswire 8:00 AM

-- March 5, 2026 --

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences Globe Newswire 7:30 AM

-- March 4, 2026 --

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome Business Wire 5:06 PM
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome Globe Newswire 5:05 PM

-- February 24, 2026 --

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference Business Wire 4:01 PM

-- February 11, 2026 --

Biogen Announces Board Chair Transition Globe Newswire 5:00 PM

-- February 8, 2026 --

Biologics License Application for Subcutaneous Formulation of "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China Globe Newswire 9:00 PM

-- February 5, 2026 --

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Avantor, Inc. (AVTR), Baxter International Inc. (BAX), Biogen Inc. (BIIB), and CarMax, Inc. (KMX) Globe Newswire 10:50 AM

-- February 4, 2026 --

Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 Business Wire 4:01 PM
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy Globe Newswire 7:30 AM

-- January 28, 2026 --

Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options Globe Newswire 7:30 AM

-- January 25, 2026 --

FDA Accepts LEQEMBI IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review PRNewswire 6:30 PM
FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review Globe Newswire 6:30 PM

-- January 12, 2026 --

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA (nusinersen) for Spinal Muscular Atrophy Globe Newswire 11:05 AM

-- January 11, 2026 --

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome Business Wire 2:00 PM

-- January 5, 2026 --

Biologics License Application for Subcutaneous Formulation of "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China Globe Newswire 8:00 PM

-- December 12, 2025 --

Annual Changes to the Nasdaq-100 Index Globe Newswire 8:00 PM

-- December 8, 2025 --

"LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List Globe Newswire 6:30 PM

-- December 5, 2025 --

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting Business Wire 9:00 AM
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting Globe Newswire 9:00 AM

-- December 3, 2025 --

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 PRNewswire 6:10 PM
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Globe Newswire 6:10 PM

-- December 2, 2025 --

New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI (lecanemab-irmb) on Neurotoxic A Protofibrils in CSF PRNewswire 4:40 PM
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI (lecanemab-irmb) on Neurotoxic A Protofibrils in CSF Globe Newswire 4:40 PM

-- December 1, 2025 --

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting Globe Newswire 7:30 AM
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting Business Wire 7:30 AM

-- November 27, 2025 --

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI" for the Treatment of Early Alzheimer's Disease in Japan Globe Newswire 7:30 PM

-- November 25, 2025 --

Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status PRNewswire 7:30 AM
Eisai Completes Rolling Submission to US FDA for LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status Globe Newswire 7:30 AM

-- November 24, 2025 --

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions Globe Newswire 7:30 AM

-- November 20, 2025 --

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference Globe Newswire 7:30 AM

-- November 17, 2025 --

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments Business Wire 7:30 AM
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments Globe Newswire 7:30 AM
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy Globe Newswire 6:00 AM

-- November 14, 2025 --

Biogen Completes Acquisition of Alcyone Therapeutics Globe Newswire 4:05 PM

-- November 13, 2025 --

"LEQEMBI" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom Globe Newswire 6:30 PM

-- November 3, 2025 --

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025 Globe Newswire 7:30 AM

-- October 26, 2025 --

Health Canada Grants Authorization for "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Globe Newswire 7:30 PM

-- October 24, 2025 --

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio Globe Newswire 7:30 AM

-- October 22, 2025 --

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 Globe Newswire 7:30 AM

-- October 13, 2025 --

LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" PRNewswire 7:30 PM
LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" Globe Newswire 7:30 PM
Market Data Delayed 15 Minutes